Propanc Bio Financials
This page shows Propanc Bio (PPCB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Propanc Bio's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Propanc Bio carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Propanc Bio's current ratio of 1.50 is below the typical benchmark, resulting in a score of 25/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Propanc Bio generates a -423.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Propanc Bio passes 3 of 9 financial strength tests. 1 of 3 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Propanc Bio generates $0.01 in operating cash flow (-$405K OCF vs -$58.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Propanc Bio earns $-101.6 in operating income for every $1 of interest expense (-$57.3M vs $564K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Propanc Bio reported -$58.9M in net income in fiscal year 2025.
Propanc Bio earned $-14.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.0% from the prior year.
Cash & Balance Sheet
Propanc Bio held $12K in cash against $538K in long-term debt as of fiscal year 2025.
Propanc Bio had 12M shares outstanding in fiscal year 2025. This represents an increase of 145411.1% from the prior year.
Margins & Returns
Propanc Bio's ROE was -423.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Propanc Bio invested $224K in research and development in fiscal year 2025. This represents a decrease of 9.8% from the prior year.
PPCB Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $20K0.0% | $20K-66.8% | $60K | N/A | $54K-0.5% | $54K-11.9% | $62K | N/A |
| SG&A Expenses | $3.6M0.0% | $3.6M-21.1% | $4.6M | N/A | $53.1M+34451.1% | $154K-30.4% | $221K | N/A |
| Operating Income | $3.7M+200.0% | -$3.7M+21.8% | -$4.7M | N/A | -$53.1M-24798.4% | -$213K+26.6% | -$291K | N/A |
| Interest Expense | $653-98.9% | $59K-80.7% | $306K | N/A | $104K-12.5% | $119K+37.9% | $86K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $3.1M+200.0% | -$3.1M+36.1% | -$4.8M | N/A | -$54.1M | N/A | N/A | N/A |
| EPS (Diluted) | $0.30+200.0% | $-0.30+23.1% | $-0.39 | N/A | $-12.50 | $-32.23 | $-35.97 | N/A |
PPCB Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.1M0.0% | $15.1M-15.9% | $18.0M-8.4% | $19.6M-12.9% | $22.5M+28585.2% | $79K+23.4% | $64K-12.1% | $72K |
| Current Assets | $7.7M0.0% | $7.7M-12.1% | $8.8M+4.9% | $8.4M-14.2% | $9.7M+54037.3% | $18K-16.5% | $22K-15.4% | $25K |
| Cash & Equivalents | $561K0.0% | $561K-6.9% | $603K+4886.2% | $12K-76.2% | $51K+246.9% | $15K+57.9% | $9K-56.0% | $21K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.7M0.0% | $3.7M+1.2% | $3.6M-36.9% | $5.7M+29.1% | $4.4M+4.7% | $4.2M+1.6% | $4.2M+8.3% | $3.9M |
| Current Liabilities | $3.6M0.0% | $3.6M+1.4% | $3.6M-36.0% | $5.6M+28.5% | $4.3M+4.5% | $4.2M+1.3% | $4.1M+8.1% | $3.8M |
| Long-Term Debt | $55K0.0% | $55K-48.6% | $107K-80.1% | $538K+22.7% | $439K+7.0% | $410K+7.3% | $382K-4.4% | $399K |
| Total Equity | $10.5M0.0% | $10.5M-27.2% | $14.4M+3.3% | $13.9M-23.1% | $18.1M+535.0% | -$4.2M-1.2% | -$4.1M-8.7% | -$3.8M |
| Retained Earnings | $134.5M+200.0% | -$134.5M-3.1% | -$130.5M-3.9% | -$125.6M-3.3% | -$121.6M-80.1% | -$67.5M-0.6% | -$67.1M-0.5% | -$66.7M |
PPCB Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.9M+394.1% | -$999K+48.5% | -$1.9M-7032.6% | -$27K+83.1% | -$161K-960.7% | $19K+108.0% | -$236K+9.4% | -$260K |
| Capital Expenditures | $5K+109.9% | $2K-9.0% | $2K | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $2.9M+392.9% | -$1.0M+48.4% | -$1.9M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $5K+309.9% | -$2K+9.0% | -$2K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $3.5M+261.8% | $965K-61.8% | $2.5M+32478.3% | $8K-96.3% | $212K+287.6% | $55K-74.6% | $216K-14.1% | $251K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PPCB Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 29.6%+59.2pp | -29.6%+4.1pp | -33.7% | N/A | -298.8% | N/A | N/A | N/A |
| Return on Assets | 20.5%+40.9pp | -20.5%+6.5pp | -26.9% | N/A | -240.0% | N/A | N/A | N/A |
| Current Ratio | 2.130.0 | 2.13-0.3 | 2.45+1.0 | 1.50-0.7 | 2.24+2.2 | 0.000.0 | 0.010.0 | 0.01 |
| Debt-to-Equity | 0.010.0 | 0.010.0 | 0.01-0.0 | 0.04+0.0 | 0.02+0.1 | -0.100.0 | -0.09+0.0 | -0.11 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Propanc Bio profitable?
No, Propanc Bio (PPCB) reported a net income of -$58.9M in fiscal year 2025.
How much debt does Propanc Bio have?
As of fiscal year 2025, Propanc Bio (PPCB) had $12K in cash and equivalents against $538K in long-term debt.
What is Propanc Bio's return on equity (ROE)?
Propanc Bio (PPCB) has a return on equity of -423.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Propanc Bio's operating cash flow?
Propanc Bio (PPCB) generated -$405K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Propanc Bio's total assets?
Propanc Bio (PPCB) had $19.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Propanc Bio spend on research and development?
Propanc Bio (PPCB) invested $224K in research and development during fiscal year 2025.
What is Propanc Bio's current ratio?
Propanc Bio (PPCB) had a current ratio of 1.50 as of fiscal year 2025, which is considered adequate.
What is Propanc Bio's debt-to-equity ratio?
Propanc Bio (PPCB) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Propanc Bio's return on assets (ROA)?
Propanc Bio (PPCB) had a return on assets of -300.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Propanc Bio's cash runway?
Based on fiscal year 2025 data, Propanc Bio (PPCB) had $12K in cash against an annual operating cash burn of $405K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Propanc Bio's Piotroski F-Score?
Propanc Bio (PPCB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Propanc Bio's earnings high quality?
Propanc Bio (PPCB) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Propanc Bio cover its interest payments?
Propanc Bio (PPCB) has an interest coverage ratio of -101.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Propanc Bio?
Propanc Bio (PPCB) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.